<DOC>
	<DOCNO>NCT00072930</DOCNO>
	<brief_summary>The primary objective study : 1 . To explore antitumor activity MEDI-522 combination docetaxel , prednisone , zoledronic acid patient metastatic Androgen-Independent Prostate Cancer ( AIPC ) ; 2 . To summarize safety MEDI-522 combination docetaxel , prednisone , zoledronic acid patient population .</brief_summary>
	<brief_title>MEDI-522 Treatment Patients With Metastatic Androgen-Independent Prostate Cancer</brief_title>
	<detailed_description>This Phase II , randomize , open-label , two-arm , multicenter study MEDI-522 combination docetaxel , prednisone , zoledronic acid patient metastatic AIPC .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Adult men least 18 year age time randomization . Metastatic , histologically cytologically confirm adenocarcinoma prostate progress start androgen deprivation therapy , include prior orchiectomy medical castration use leuteinizing hormonereleasing hormone ( LHRH ) antagonists leuprolide goserelin ( patient must remain LHRH analogue therapy duration study surgically castrate ) . Progressive disease document : a. PSA progression ( define two consecutive increase PSA previous reference value , first increase PSA occur minimum 1 week reference value [ obtain within 2 month prior study randomization ] confirm subsequent increase PSA whose value must ³ 5 ng/mL prior study randomization ) ; 41 one following : . Bone metastasis ( define ³3 focus bone scan confirm radiologically within 1 month prior study randomization ) ; ii . Measurable nonbony metastatic disease ( documented radiographic study perform within 1 month prior study randomization ) . Serum testosterone level &lt; 50 ng/dL document nonsurgically castrated patient within 21 day prior randomization . Prior treatment nonsteroidal antiandrogens ( e.g. , flutamide bicalutamide ) allow provide : There evidence disease progression ( define Inclusion Criteria # 2 ) follow withdrawal antiandrogens ; b . At least 4 week flutamide 6 week bicalutamide pass since last treatment . Prior treatment ketoconazole and/or steroid allow provide least 4 week pass since last treatment . There restriction use prednisone ( 5 mg twice daily ) another functionally equivalent oral corticosteroid treatment pain . In rare instance patient potent , must agree practice effective method contraception include condom abstinence , unless sexual partner sterile , time first administration MEDI522 docetaxel 30 day last dose either docetaxel MEDI522 , whichever last drug discontinue . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 document within 21 day prior randomization . Life expectancy , opinion investigator , least 6 month . White blood cell ( WBC ) count ≥ 3,000/mm3 ; absolute neutrophil count ( ANC ) ≥ 1,500/mm3 ; platelet count ≥ 100,000/mm3 ; hemoglobin ³ 9 g/dL document within 21 day prior randomization . Bilirubin ≤ ULN ; aspartate transaminase ( AST ) /alanine transaminase ( ALT ) £1.5 time ULN AST/ALT &gt; 1.5 time ULN , alkaline phosphatase must £2.5 time ULN ; serum creatinine ≤ 1.5 mg/dL ; INR within normal range , unless patient receive anticoagulation therapy ; correct serum calcium 8.011.5 mg/dL document within 21 day prior randomization . Patients prior major surgery eligible least 4 week pass since surgery surgical wound heal prior study randomization . Prior radiotherapy include therapeutic isotope allow provide measurable evaluable disease clearly progress present acute radiationrelated toxicity resolve prior study randomization . Prior treatment unconventional therapy malignancy ( e.g. , vitamin , St. John 's Wort , PCSPES , saw palmetto , herbal remedy ) allow provide least 4 week pass since last treatment prior randomization . Written inform consent HIPAA authorization ( USA sit ) obtain patient prior receipt study medication begin study procedure . Prior chemotherapy metastatic prostate cancer ( prior adjuvant chemotherapy allow provide nontaxane base least 6 month pass since last treatment ) . Prior treatment investigational agent within 4 week prior randomization . Planned concurrent treatment unconventional therapy malignancy ( e.g. , vitamin , St. John 's Wort , PCSPES , saw palmetto , herbal herbal remedy ) base medical history . Currently require anticoagulation ( exclude use heparin flush solution maintenance catheter line ) thromboembolic disease base medical history physical examination . Current plan participation ( time randomization 30 day last dose either docetaxel MEDI522 , whichever last drug discontinue ) research protocol investigational agent therapy may administer . Any evidence history elicit investigator prior treatment MEDI522 MEDI523 . Prior treatment calcitonin , mithramycin , gallium nitrate within 2 week prior randomization . Clinically evident central nervous system ( CNS ) metastasis . History prior malignancy within past 5 year adequately treat basal cell squamous cell skin cancer Stage I II cancer currently complete remission ; Any evidence history elicit investigator symptomatic cerebrovascular event ( i.e. , stroke transient ischemic attack ) within 6 month prior randomization ; history evidence pulmonary embolism thrombophlebitis ( include deep vein thrombosis ) require anticoagulant therapy ( e.g. , warfarin heparin ) . Any evidence history elicit investigator myocardial infarction angina within 6 month prior randomization . Any evidence history elicit investigator hematemesis , melena , hematochezia , uncontrolled gross hematuria within 4 week prior randomization . Any evidence history elicit investigator bleeding diatheses . Major elective surgery plan time randomization 30 day last dose either docetaxel MEDI522 , whichever last drug discontinue . Any evidence history elicit investigator hypersensitivity previously administer monoclonal antibody . Any evidence history elicit investigator hypersensitivity drug formulate polysorbate 80 , prednisone ( functionally equivalent oral corticosteroid ) , zoledronic acid . Known human immunodeficiency virus ( HIV ) know active viral hepatic infection base medical history physical examination . Any evidence history elicit investigator uncontrolled refractory hypertension uncontrolled diabetes despite medication within 6 month prior randomization . Any evidence history elicit investigator active infection require parenteral antiinfective therapy . A general medical psychological condition behavior , include substance dependence abuse , opinion investigator , might permit patient complete study sign inform consent .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
</DOC>